{"id":599136,"date":"2022-05-09T20:32:02","date_gmt":"2022-05-09T20:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=599136"},"modified":"2022-05-09T20:32:02","modified_gmt":"2022-05-09T20:32:02","slug":"recurrent-glioblastoma-market-to-accelerate-substantially-during-the-forecast-period-delveinsight-key-companies-apogenix-tocagen-pharmabcine-celgene-delmar-pharma-abbvie-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/recurrent-glioblastoma-market-to-accelerate-substantially-during-the-forecast-period-delveinsight-key-companies-apogenix-tocagen-pharmabcine-celgene-delmar-pharma-abbvie-and-others_599136.html","title":{"rendered":"Recurrent Glioblastoma Market to Accelerate Substantially During the Forecast Period – DelveInsight | Key Companies – Apogenix, Tocagen, PharmAbcine, Celgene, DelMar Pharma, AbbVie, and Others"},"content":{"rendered":"
\n
\"Recurrent<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Recurrent Glioblastoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Recurrent Glioblastoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Recurrent Glioblastoma market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Recurrent<\/p>\n

Recurrent Glioblastoma: An Overview<\/strong><\/p>\n

According to the American Brain Tumor Association, Glioblastomas (also called GBM) are malignant Grade IV tumors, where a large portion of tumor cells reproduce and divide at any given time. The tumor is predominantly made up of abnormal astrocytic cells, which also contain a mixture of different cell types (including blood vessels) and areas of dead cells (necrosis). <\/em><\/p>\n

The mainstay of treatment for GBM is surgery, followed by radiation and chemotherapy. The primary objective of surgery is to remove as much of the tumor as possible without injuring the surrounding normal brain tissue needed for normal neurological function (such as motor skills, the ability to speak and walk, etc.).<\/em><\/p>\n

Recurrent glioblastoma is a possibility that oncologists and patients must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that cancer might come back after a period of remission. Glioblastoma can come back anywhere in the brain or spinal cord. However, most recurrences are found near the site of the original tumor.<\/em><\/p>\n

Recurrent Glioblastoma Market Key Facts<\/strong><\/p>\n